^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PORT-6

    i
    Other names: PORT-6, TT-10
    Associations

    News

    Trials
    Company:
    Portage
    Drug class:
    Adenosine A2A receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    ADPORT-601: TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Portage Biotech | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PORT-6
    over1year
    TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Portage Biotech | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PORT-6
    over2years
    TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Tarus Therapeutics, Inc. | Initiation date: Sep 2021 --> Aug 2022
    Trial initiation date
    |
    CD4 (CD4 Molecule)
    |
    PORT-6
    almost3years
    Adenosine receptor antagonists A2AR (TT-10) and A2BR (TT-4) demonstrate anti-tumor activity in 4T1-induced syngeneic breast cancer mouse model (AACR 2022)
    TT-10 & TT-4 alone was superior (p<0.05) to the VC as well as single agent anti-PD-1 in slowing tumor growth, which was further supported by the increase in T-cell activity observed in the end of study TIL analysis. Lastly, striking reductions in MDSC populations were also observed in both TT-10 & TT-4 treated mice, when compared to single agent anti-PD-1 and the VC.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ITGAM (Integrin, alpha M) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    PORT-6 • PORT-7
    over3years
    TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Tarus Therapeutics, Inc.
    Clinical • New P1/2 trial
    |
    CD4 (CD4 Molecule)
    |
    PORT-6